A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients — Stella

Home/NHL, Adult/

View on ClinicalTrials.gov

Recruiting

Back to NHL, Adult trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

China

Henan Cancer Hospital, Zhengzhou, Henan

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality

Key details

Phase

Early testing

Sponsor

Shengke Pharmaceuticals (Jiangsu) Limited, China

Enrollment target

~60 participants

Started

November 2022

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated May 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.